J&J Sees 82% Surge in Q1 Sales of Yuhan's LECLAZA Combination Therapy

LECLAZA (ingredient: lazertinib), a lung cancer treatment developed by Yuhan Corporation and licensed out, is strengthening its presence in the global market, particularly through combination therapy with RYBREVANT (ingredient: amivantamab).

According to the industry on April 15, Johnson & Johnson’s (J&J) revenue from the LECLAZA and RYBREVANT combination therapy in the first quarter of this year soared by 82% year-on-year to 257 million dollars (approximately 378.6 billion won). Compared to the previous quarter, revenue increased by 19%.

원본보기 아이콘

By region, sales in the United States reached 175 million dollars (approximately 257.8 billion won), up 55.1% from the same period last year. Overseas sales grew by more than 100% year-on-year to 82 million dollars (approximately 120.8 billion won).

The LECLAZA and RYBREVANT combination therapy was cited as one of the key products driving growth in J&J's oncology segment. In its earnings announcement, J&J stated that the LECLAZA combination therapy, along with DARZALEX (ingredient: daratumumab) and CARVYKTI (ingredient: ciltacabtagene autoleucel), led the growth of its innovative medicines division.

J&J’s total first-quarter revenue was 24.062 billion dollars (approximately 35.482 trillion won), up 9.9% from the same period last year. The innovative medicines division posted 15.426 billion dollars (22.7471 trillion won), an increase of 11.2% year-on-year.

LECLAZA is a third-generation EGFR-targeted anticancer drug independently developed by Yuhan Corporation. In 2018, Yuhan licensed the drug out to Janssen, a J&J affiliate. Under the terms of the agreement, Yuhan receives royalties linked to J&J’s global sales, meaning that the growth in combination therapy revenue directly impacts Yuhan’s earnings.

The LECLAZA and RYBREVANT combination therapy received U.S. Food and Drug Administration (FDA) approval in 2024 and is now moving into full-scale global commercialization.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.